LB Pharmaceuticals Inc (LBRX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, LB Pharmaceuticals reported revenue of $0. Net income was -$25.2M, or -$3.13 per diluted share. Operating activities generated -$35.2M of cash, leaving -$35.3M of free cash flow. At fiscal year end, LB Pharmaceuticals held $312.9M in total assets against $11.6M in total liabilities, including $250.2M of cash and equivalents.
Open the full interactive LB Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
LB Pharmaceuticals Key Stats
| Share Price | $34.79 |
|---|---|
| Market Cap | $1.05B |
| 52-Week Range | $14.61 – $49.48 |
| Shares Outstanding | 30.1 million (basic, 2026 Q2) |
LB Pharmaceuticals Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Pre-Tax Income | -$25.2M |
| Income Tax | $1,000 |
| Net Income | -$25.2M |
| Diluted EPS | -$3.13 |
LB Pharmaceuticals Quarterly Results
| 2025 Q3 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Income | -$3.6M | -$19.1M | -$51.6M |
| Diluted EPS | -$0.61 | -$0.67 | -$1.71 |
LB Pharmaceuticals Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $250.2M |
| Current Assets | $308.4M |
| Total Assets | $312.9M |
| Current Liabilities | $7.4M |
| Total Liabilities | $11.6M |
| Shareholders' Equity | $301.3M |
LB Pharmaceuticals Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$35.2M |
| Cash From Investing | -$39.9M |
| Cash From Financing | $302.6M |
| Free Cash Flow | -$35.3M |
Figures from LB Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full LB Pharmaceuticals financials page for every line item.
LB Pharmaceuticals Company Profile
| Ticker | LBRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001691082 |
Frequently Asked Questions
What was LB Pharmaceuticals' revenue in fiscal 2025?
LB Pharmaceuticals (LBRX) reported revenue of $0 for fiscal 2025.
What was LB Pharmaceuticals' net income in fiscal 2025?
LB Pharmaceuticals reported net income of -$25.2M for fiscal 2025.
What was LB Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
LB Pharmaceuticals' diluted EPS was -$3.13 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did LB Pharmaceuticals generate in fiscal 2025?
LB Pharmaceuticals generated -$35.3M of free cash flow in fiscal 2025.
What was LB Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), LB Pharmaceuticals reported revenue of $0.
How many shares of LB Pharmaceuticals are outstanding?
LB Pharmaceuticals reported a weighted average of 30.1 million basic shares outstanding in 2026 Q2.
What is LB Pharmaceuticals' market cap?
Based on its latest closing price, LB Pharmaceuticals (LBRX) has a market capitalization of about $1.05B.
When does LB Pharmaceuticals' fiscal year end?
LB Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is LB Pharmaceuticals headquartered?
LB Pharmaceuticals lists its business address in New York, New York in its SEC filings.